Gene expression data of patients with endocrine-resistant breast cancer
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
Yes
Type of personal data:
Genetic data, Health data related to cancer diagnosis
Code key exists:
Yes
Sensitive personal data:
Yes
Citation:
Language:
Method and outcome
Method and outcome
Population:
Patients with endocrine-resistant breast cancer in Stockholm, Sweden.
Study design:
- Experimental study
Description of study design:
Patients with endocrine-resistant breast cancer in Stockholm, Sweden. RNA obtained from patients primary and relapse tumors. RNA was extracted from formalin-fixed paraffin-embedded tumor tissue and analyzed by Affymetrix Clariom D Microarray. Pre-processing carried out in Transcriptome Analysis Console with SST-RMA method.
Description of sampling:
Retrospective collection of patients with endocrine-resistant breast cancer diagnosed in Stockholm, Sweden. Primary and relapse tumors from the same patient were identified from the pathology laboratory information system at Karolinska University Hospital, Stockholm, Sweden.
Number of individuals/objects:
3
Data format/data structure:
Samples/material - Existing from scientific collection/biobank
Samples/material - Existing from scientific collection/biobank
Name:
Type(s) of sample:
Geographic coverage
Geographic coverage
Geographic location:
Administrative information
Administrative information
Responsible department/unit:
Department of Oncology-Pathology [K7]
Contributor(s):
Ethics Review:
Stockholm - 2015/1768-31/2
Funding
Funding
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROROpens in a new tab
Award number:
2023-03009_VR
Award title:
Identification of tumor characteristics influencing long-term risk of distant metastatic disease and endocrine treatment benefit in ER+ breast cancer
Funding information:
Most breast cancer patients are diagnosed with hormone-dependent (estrogen receptor-positive, ER+) breast cancer and endocrine treatment is standard of care. A unique feature of ER+ disease is that the risk to develop distant metastasis remains stable beyond 5-10 years after diagnosis, and half or more of all metastases will be diagnosed after this initial follow-up. The tumor biological factors underlying long-term risk are poorly understood, and it will remain a considerable clinical challenge in the foreseeable future. We will investigate the influence of standard clinical markers, their intra-tumor heterogeneity, and the heterogeneous ER+ tumor microenvironment, to identify tumor characteristics influencing long-term risk and benefit from endocrine treatment. Novel deep-learning methods will be used and in depth spatial analysis will enable understanding of tumor biology down to single-cell level. We will use unique and large clinical trials with patients randomized to endocrine treatment versus not with complete long-term follow-up. The distinction of long-term risk is essential, since accurate risk prediction allows for individualized treatment, decreases anxiety, and supports aggressive treatment for patients at high risk of fatal disease. Our study has the potential to answer vital questions about the influence of the tumor microenvironment and intra-tumor heterogeneity for long-term risk in ER+ breast cancer, helped by the interdisciplinary expertise in our team.
Topic and keywords
Topic and keywords
Standard för svensk indelning av forskningsämnen 2025:
Publications
Publications
Citation:
ISBN:
9789180179720
